Eupraxia Pharmaceuticals Statistics
Total Valuation
EPRX has a market cap or net worth of $416.76 million. The enterprise value is $365.26 million.
Important Dates
The next estimated earnings date is Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
EPRX has 61.50 million shares outstanding. The number of shares has increased by 17.76% in one year.
| Current Share Class | 61.50M |
| Shares Outstanding | 61.50M |
| Shares Change (YoY) | +17.76% |
| Shares Change (QoQ) | +38.96% |
| Owned by Insiders (%) | 18.14% |
| Owned by Institutions (%) | 24.23% |
| Float | 45.63M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 5.18 |
| P/TBV Ratio | 7.97 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 15.12, with a Debt / Equity ratio of 0.00.
| Current Ratio | 15.12 |
| Quick Ratio | 14.43 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -68.76% and return on invested capital (ROIC) is -42.70%.
| Return on Equity (ROE) | -68.76% |
| Return on Assets (ROA) | -39.67% |
| Return on Invested Capital (ROIC) | -42.70% |
| Return on Capital Employed (ROCE) | -47.73% |
| Weighted Average Cost of Capital (WACC) | 11.82% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$838,918 |
| Employee Count | 49 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, EPRX has paid $19,091 in taxes.
| Income Tax | 19,091 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +123.17% in the last 52 weeks. The beta is 1.38, so EPRX's price volatility has been higher than the market average.
| Beta (5Y) | 1.38 |
| 52-Week Price Change | +123.17% |
| 50-Day Moving Average | 7.85 |
| 200-Day Moving Average | 6.49 |
| Relative Strength Index (RSI) | 38.11 |
| Average Volume (20 Days) | 197,054 |
Short Selling Information
The latest short interest is 2.50 million, so 4.07% of the outstanding shares have been sold short.
| Short Interest | 2.50M |
| Short Previous Month | 1.98M |
| Short % of Shares Out | 4.07% |
| Short % of Float | 5.48% |
| Short Ratio (days to cover) | 8.76 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -38.43M |
| Pretax Income | -38.59M |
| Net Income | -41.11M |
| EBITDA | -38.27M |
| EBIT | -38.43M |
| Earnings Per Share (EPS) | -$1.03 |
Full Income StatementBalance Sheet
The company has $80.56 million in cash and $154,362 in debt, with a net cash position of $80.41 million or $1.31 per share.
| Cash & Cash Equivalents | 80.56M |
| Total Debt | 154,362 |
| Net Cash | 80.41M |
| Net Cash Per Share | $1.31 |
| Equity (Book Value) | 80.45M |
| Book Value Per Share | 1.01 |
| Working Capital | 79.47M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.55 million and capital expenditures -$588,947, giving a free cash flow of -$29.14 million.
| Operating Cash Flow | -28.55M |
| Capital Expenditures | -588,947 |
| Depreciation & Amortization | 164,404 |
| Net Borrowing | n/a |
| Free Cash Flow | -29.14M |
| FCF Per Share | -$0.47 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
EPRX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -17.76% |
| Shareholder Yield | -17.76% |
| Earnings Yield | -9.86% |
| FCF Yield | -6.99% |
Analyst Forecast
The average price target for EPRX is $15.00, which is 125.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $15.00 |
| Price Target Difference | 125.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
